Get the Stockscreener App
191.16
1.22%
-2.355
Revolution Medicines Inc stock is traded at $191.16, with a volume of 717.20K.
It is down -1.22% in the last 24 hours and down -6.69% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
See More
Previous Close:
$193.52
Open:
$193.31
24h Volume:
717.20K
Relative Volume:
0.33
Market Cap:
$40.97B
Revenue:
$742.00K
Net Income/Loss:
$-1.37B
P/E Ratio:
-27.03
EPS:
-7.0731
Net Cash Flow:
$-1.07B
1W Performance:
+1.62%
1M Performance:
-6.69%
6M Performance:
+25.32%
1Y Performance:
+285.72%
1-Day Range:
$189.37
$195.94
1-Week Range:
$184.37
$197.00
52-Week Range:
$47.45
$224.31
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
650-481-6801
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
191.16 | 40.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
509.86 | 129.23B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.75 | 94.92B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.00 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.32 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.60 | 42.04B | 5.76B | 514.49M | 1.10B | 4.4813 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-26 | Resumed | Goldman | Buy |
| Sep-10-26 | Initiated | Morgan Stanley | Overweight |
| May-22-26 | Initiated | Bernstein | Mkt Perform |
| May-18-26 | Resumed | Truist | Buy |
| Mar-16-26 | Resumed | Jefferies | Buy |
| Feb-27-26 | Resumed | UBS | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-03-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-12-25 | Resumed | Raymond James | Strong Buy |
| Sep-05-25 | Initiated | Truist | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Aug-15-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
About 3% of U.S. patients with metastatic pancreatic cancer survive five years. A drug pair starts testing in patients. - Stock Titan
Revolution Medicines (NasdaqGS:RVMD) Stock Forecast & Analyst Predictions - Simply Wall Street
Revolution Medicines’ CDO Sandler sells $1.2m in stock - Investing.com
Form 4 Revolution Medicines Inc For: 1 October By Investing.com - Investing.com UK
Revolution Medicines SVP Cislini sells $158,599 in shares By Investing.com - Investing.com Nigeria
Form 4 Revolution Medicines Inc For: 29 September By Investing.com - Investing.com South Africa
Revolution Medicines SVP Cislini sells $158,599 in shares - Investing.com
Form 4 Revolution Medicines Inc For: 29 September By Investing.com - Investing.com UK
Revolution Medicines SVP Jeff Cislini Sells 765 Shares Under 10b5-1 Trading Plan - Kalkine Media
Revolution Medicines (RVMD) counsel Jeff Cislini sold 765 shares at $207.3201 each under a trading plan. - Stock Titan
6,000 shares from exercised options are listed for an officer’s proposed sale at Revolution Medicines (RVMD). - Stock Titan
Form 4 Revolution Medicines Inc For: 28 September By Investing.com - Investing.com South Africa
Form 4 Revolution Medicines Inc For: 28 September By Investing.com - Investing.com Nigeria
Revolution Medicines officer Mancini sells $743k in stock - Investing.com
Form 4 Revolution Medicines Inc For: 28 September By Investing.com - Investing.com UK
Stock options are the source of 9,363 shares a Revolution Medicines (RVMD) officer proposes to sell. - Stock Titan
Revolution Medicines director Elizabeth Anderson sells $1.96m in stock - Investing.com
Revolution Medicines (RVMD) director exercises options for 5,070 shares and sells 10,143 shares. - Stock Titan
After three earlier sales, an officer proposes selling 587 more Revolution Medicines (RVMD) shares. - Stock Titan
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes - Yahoo Finance
Form 4 Revolution Medicines Inc For: 22 September By Investing.com - Investing.com Canada
Revolution Medicines (NASDAQ: RVMD) director plans stock sale from option exercise - Stock Titan
Revolution Medicines chief development officer sells $67,940 in stock - Investing.com
Revolution Medicines officer sells $353,449 in shares - Investing.com
Revolution Medicines COO Margaret Horn sells $989,612 of common stock - Investing.com
Revolution Medicines’ senior advisor sells $1.1m in stock - Investing.com
Revolution Medicines CEO Mark Goldsmith sells $2.78m in stock - Investing.com
Revolution Medicines’ Jeff Cislini sells $670k in common stock - Investing.com
Revolution Medicines CFO Jack Anders sells $807,513 in stock - Investing.com
Revolution Medicines (RVMD) exec sells 1,774 shares, keeps 39,575 RSUs - Stock Titan
Revolution Medicines (RVMD) legal chief makes pre-set stock sale for taxes - Stock Titan
Revolution Medicines (RVMD) insider adds new sale after multimillion-dollar trades - Stock Titan
Revolution Medicines (RVMD) CFO sells shares under tax-driven plan - Stock Titan
Officer at Revolution Medicines (RVMD) plans 331-share sale - Stock Titan
Revolution Medicines officer plans $484K sale | RVMD SEC FilingForm 144 - Stock Titan
Officer at Revolution Medicines (NASDAQ: RVMD) plans 4,830-share stock sale after RSU vesting - Stock Titan
Over $16M in recent stock sales as Revolution Medicines (NASDAQ: RVMD) filer Mark A. Goldsmith plans another trade - Stock Titan
Revolution Medicines (RVMD) exec exercises options, sells stock - Stock Titan
(RVMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Revolution Medicines director Lorence Kim sells $3.58m in stock By Investing.com - Investing.com South Africa
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs - Yahoo Finance
Abu Dhabi Investment Council Co P.J.S.C's Revolution Medicines Inc(RVMD) Holding History - GuruFocus
Revolution Medicines (NASDAQ: RVMD) officer plans multi-million stock option share sale - Stock Titan
Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Revolution Medicines director Lorence Kim sells $3.58m in stock By Investing.com - Investing.com Australia
Revolution Medicines director Lorence Kim sells $3.58m in stock By Investing.com - Investing.com Canada
Revolution Medicines director Lorence Kim sells $3.58m in stock - investing.com
Revolution Medicines Director Lorence H. Kim Sells 14,090 Shares via Revocable Trust Under 10b5-1 Plan - Kalkine Media
Planned multimillion stock sale at Revolution Medicines (RVMD) - Stock Titan
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Revolution Medicines Inc Stock (RVMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ALAN SANDLER | Officer |
Sep 29 '26 |
Proposed Sale |
201.74 |
6,309 |
1,272,778 |
0 |
| Sandler Alan B. | Chief Development Officer |
Sep 29 '26 |
Sale |
202.14 |
6,309 |
1,275,294 |
52,559 |
| Mancini Anthony | See Remarks |
Sep 25 '26 |
Option Exercise |
33.62 |
3,121 |
104,928 |
42,886 |
| Mancini Anthony | See Remarks |
Sep 25 '26 |
Sale |
200.54 |
3,121 |
625,885 |
39,765 |
| ANTHONY MANCINI | Officer |
Sep 25 '26 |
Proposed Sale |
199.86 |
9,363 |
1,871,289 |
0 |
| Cislini Jeff | SVP & General Counsel |
Sep 25 '26 |
Sale |
207.32 |
765 |
158,600 |
51,776 |
| ANTHONY MANCINI | Officer |
Sep 24 '26 |
Proposed Sale |
190.74 |
587 |
111,964 |
0 |
| Mancini Anthony | See Remarks |
Sep 24 '26 |
Sale |
200.00 |
587 |
117,400 |
39,765 |
| ANDERSON ELIZABETH M | Director |
Sep 22 '26 |
Sale |
193.04 |
10,143 |
1,958,016 |
4,333 |
| ANDERSON ELIZABETH M | Director |
Sep 22 '26 |
Option Exercise |
1.12 |
5,070 |
5,678 |
14,476 |
5.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):